FGI-104
Small Molecule Inhibitor of Hepatitis C (HCV) and Hepatitis B (HBV) Viruses
The FGI-104 program is developing a small molecule inhibitors of infections by HCV and HBV viruses. This product candidate demonstrates potent efficacy against HCV, HBV and against other lethal viruses.
FGI-104 Inhibition of Hepatitis C Virus. Cell-based assays were conducted to evaluate HCV propagation in the presence of FGI-103.
FGI-104 protects animals from a lethal infection with Ebola virus. The red squares demonstrate that treatment with FGI-104 prevents Ebola-mediated death.